
Monster Beverage slips about 3% after Americas CEO Rob Gehring resigns to rejoin Coca-Cola
The stock fell on the Sept 28 news, though 20% Q2 sales growth keeps the fundamental case intact. A premarket rebound could not be verified.
Daily Digest
Daily Digest
Pomegra Briefs - Page 27 of 52
Short, sourced summaries of the biggest market stories - what happened, why it matters, the key numbers, and what to watch next

The stock fell on the Sept 28 news, though 20% Q2 sales growth keeps the fundamental case intact. A premarket rebound could not be verified.

Lynas Rare Earths (LYC.AX) agreed an all-share A$968M deal for Meteoric, which jumped about 50% on the news.

France's 10-year yield near 4.8% versus Germany's 3.6% as oil, inflation and budget worries hit bonds.
Tokyo stocks rose on 30 September on US chip gains, a SoftBank surge and lower oil. The BOJ Tankan, released the following morning, showed large manufacturers at +24, up from +22 but below the +25 forecast.
Gold (XAUUSD) closed the third quarter near $4,155 an ounce as higher bond yields made it less attractive.

The Fed's watchdog found no crime in the $2.4B project, but President Trump still wants Powell off the board.

China's official factory index climbed from 49.8 in August as output grew, ending two months below 50.

Carnival (CCL) closed at $25.11 as record $8.44B revenue and a higher profit forecast eased fuel worries.

Bitcoin (BTC) ended near $84,000 while Ether (ETH) gained 71%, its best quarter since 2021, on bond buybacks.
S&P 500 (SPX) ended at 7,651.54 as ADP showed 90,000 new jobs, while the Dow lost 4.3% in September.
Hewlett Packard Enterprise (HPE) also lifted its networking outlook and Juniper savings goal to $800M.

Mattel (MAT) closed at $12.70 as Ynon Kreiz leaves to co-lead Paramount-Warner and Roger Lynch takes over.

Brent (BZ=F) holds near $97 while Mideast crude flows reach 98% of pre-war levels and Iran talks stall

Cboe (CBOE) keeps sole rights to S&P 500 options through 2051, with 2027 fee changes seen as minor.
Moderna (MRNA) sank from $203.46 to about $191 as Citi said a 222% rally assumes unrealistic cancer sales.
Page 27 of 52 · 776 briefs